Advertisement

Neuropharmacology

  • Swagata Tripathy
  • Suma Rabab Ahmad
Chapter
  • 89 Downloads

Abstract

Neuro-critical care involves the use of various drugs. Knowledge of these drugs in terms of dose, adverse effects, and use in special populations is essential for good patient care. It is imperative that medications are used appropriately during neuro-emergencies and neurological life support. The right choice of medication depends upon the knowledge of the pharmacodynamics and pharmacokinetics of the drug. Medications discussed here include antiepileptic drugs, sedatives, analgesics, neuromuscular blocking drugs, antihypertensive agents, thrombolytic agents, antiplatelets, oral anticoagulants, and hemostatic agents. Drugs used in subarachnoid hemorrhage, for reducing intracranial pressure, managing hyponatremia and myasthenia gravis are also briefly mentioned. Patients presenting with neuro-emergencies are either already consuming these drugs and having certain adverse drug reactions or the physician will have to use these for curtailing the acute episode. The chapter covers salient pearls for using these medications by first responders in the emergency department and neuro-critical care unit.

References

  1. 1.
    Glauser T, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury? Anesth Analg. 2005;101(02):524–34.PubMedGoogle Scholar
  3. 3.
    Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621–60.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4(3):507–23.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Villa FA, Citerio G. Sedation and analgesia in neurointensive care. In: Layon AJ, Gabrielli A, Friedman WA, editors. Textbook of neurointensive care, vol. 1. 2nd ed. New York: Springer; 2014.Google Scholar
  6. 6.
    Hughes CG, McGrane S, Pandharipande PP. Sedation in the intensive care setting. Clin Pharmacol. 2012;4:53–63.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Oddo M, Crippa IA, Mehta S, Menon D, Payen JF, Taccone FS, Citerio G. Optimizing sedation in patients with acute brain injury. Crit Care. 2016;20(1):128.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Vanaclocha N, Chisbert V, Quilis V, Bilotta F, Badenes R. Sedation during neurocritical care. J Neuroanaesthesiol Crit Care. 2019;06(02):056–61.Google Scholar
  9. 9.
    Baraka A. Anaesthesia and myasthenia gravis. Can J Anaesth. 1992;39(5 Pt 1):476–86.PubMedGoogle Scholar
  10. 10.
    Appleton JP, Sprigg N, Bath PM. Blood pressure management in acute stroke. Stroke Vasc Neurol. 2016;1:e000020.Google Scholar
  11. 11.
    Bowry R, Navalkele DD, Gonzales NR. Blood pressure management in stroke: five new things. Neurol Clin Pract. 2014;4(5):419–26.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Krishnan K, Scutt P, Woodhouse L, Adami A, Becker JL, Berge E, Cala LA, et al. Glyceryl trinitrate for acute intracerebral hemorrhage: results from the efficacy of nitric oxide in stroke (ENOS) trial, a subgroup analysis. Stroke. 2016;47:44–52.PubMedGoogle Scholar
  13. 13.
    Zaidi G, Chichra A, Weitzen M, Narasimhan M. Blood pressure control in neurological ICU patients: what is too high and what is too low? Open Crit Care Med J. 2013;6(1: M3):46–55.Google Scholar
  14. 14.
    Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. 2014;(10):CD006986.Google Scholar
  15. 15.
    Ismail A. How do you convert an oral pyridostigmine dose to a parenteral neostigmine dose? [Internet]. London: UK Medicines Information Pharmacist for NHS Healthcare Professionals; 2017. https://www.sps.nhs.uk/.Google Scholar
  16. 16.
    Hacke W, Kaste M, Bluhmki E, Brosman M. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.PubMedGoogle Scholar
  17. 17.
    Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL, on behalf of the American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–99.PubMedGoogle Scholar
  18. 18.
    Multicenter Acute Stroke Trial--Europe Study Group, Hommel M, Cornu C, Boutitie F, Boissel JP. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145–50.Google Scholar
  19. 19.
    Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab. 2004;24(9):945–63.PubMedGoogle Scholar
  20. 20.
    Campbell BCV, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573–82.PubMedGoogle Scholar
  21. 21.
    Verstraete M. Third generation thrombolytic drugs. Am J Med. 2000;109(1):52–8.PubMedGoogle Scholar
  22. 22.
    Singh VP, Yadav P, Malhotra M, Theengh DP, Malhotra R, Patnaik SS. Role of aspirin in the primary prevention of artherosclerotic vascular disease: a reappraisal. JIACM. 2013;14(2):143–8.Google Scholar
  23. 23.
    Arnett DK, Blumenthal RS, Albert MA, Michos ED, Buroker AB, Miedema MD, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596–646.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Sandercock PAG, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;(3):CD000029.Google Scholar
  25. 25.
    Han Y, et al. Influence of genetic polymorphism on clopidogrel response and clinical outcome in patients with acute ischemic stroke CYP2C19 genotype on clopidogrel response. CNS Neurosci Ther. 2015;21(9):692–7.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Wang Y, Minematsu K, Wong KSL, Amarenco P, Albers GW, Denison H, et al. Ticagrelor in acute stroke or transient ischemic attack in Asian patients. Stroke. 2017;48:167–73.PubMedGoogle Scholar
  27. 27.
    Paciaroni M, Agnelli G, Falocci N, Caso V, Becatti C, Marchesilli S, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke. 2015;46:2175–82.PubMedGoogle Scholar
  28. 28.
    Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ, Engelter ST, Fischer U, Norrving B. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117–26.PubMedGoogle Scholar
  29. 29.
    Brophy GM, Human T. Pharmacotherapy pearls for emergency neurological life support. Neurocrit Care. 2017;27(1):51–73.PubMedGoogle Scholar
  30. 30.
    Sarma AK, Ghoshal S, Craven SJ, Sarwal A. Intracerebral hemorrhage: a brief evidence-based review of common etiologies, mechanisms of secondary injury, and medical and surgical management. J Neuroanaesthesiol Crit Care. 2019;06(02):119–30.Google Scholar
  31. 31.
    Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D, on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032–60.Google Scholar
  32. 32.
    Jehan F, Zeeshan M, Kulvatunyou N, Khan M, O’Keeffe T, Tang A, Gries L, Joseph B. Is there a need for platelet transfusion after traumatic brain injury in patients on P2Y12 inhibitors? J Surg Res. 2019;236:224–9.PubMedGoogle Scholar
  33. 33.
    Holzmacher JL, Reynolds C, Patel M, Maluso P, Holland S, Gamsky N, et al. Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy. Brain Inj. 2018;32(3):325–30.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Barker FG, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg. 1996;84:405–14.PubMedGoogle Scholar
  35. 35.
    Kronvall E, Undren P, Romner B, Saveland H, Cronqvist M, Nilsson OG. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. J Neurosurg. 2008;110(1):58–63.Google Scholar
  36. 36.
    Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39:893–8.PubMedGoogle Scholar
  37. 37.
    Roos T. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo- controlled trial. STAR Study Group. Neurology. 2000;54:77–82.PubMedGoogle Scholar
  38. 38.
    Hillman J, Fridriksson S, Nilsson O, et al. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurismal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002;97:771–8.PubMedGoogle Scholar
  39. 39.
    Hays AN, Lazaridis C, Neyens R, Nicholas J, Gay S, Chalela JA. Osmotherapy: use among neurointensivists. Neurocrit Care. 2011;14(2):222–8.PubMedGoogle Scholar
  40. 40.
    Kheirbek T, Pascual JL. Hypertonic saline for the treatment of intracranial hypertension. Curr Neurol Neurosci Rep. 2014;14(9):482.PubMedGoogle Scholar
  41. 41.
    Simon EE. Hyponatremia treatment & management. Medscape; 2018.Google Scholar

Copyright information

© The Editor(s) (if applicable) and The Author(s)  2020

Authors and Affiliations

  • Swagata Tripathy
    • 1
  • Suma Rabab Ahmad
    • 1
  1. 1.All India Institute of Medical SciencesBhubaneshwarIndia

Personalised recommendations